Search All Tech Briefings

Search technology briefings produced by NIHR Innovation Observatory. These are short reports on new or repurposed medicines that we have already sent to our stakeholders. Only those technologies (medicines) that are within the scope of our stakeholders will have a technology briefing available. Search our technology briefings by intervention (drug or device), specific indication (disease or condition), or general therapeutic area.

| 22 Results

Clear All Filters

Title	Intervention	Indication	Therapeutic Area	Year	Actions
TAS-102 with bevacizumab for treating refractory metastatic colorectal cancer after 2 previous therapies	Bevacizumab (Avastin; R 435; RG 405; RG 435) , Lonsurf; TAS-102 (fixed dose combination: Trifluridine; Tipiracil hydrochloride)	Colorectal cancer	Gastrointestinal Cancer , Oncology	2023	View \| Download
Tanezumab for cancer pain due to bone metastasis	Tanezumab (PF-04383119; RN624)	Cancer pain	Bone and Cartilage Cancer , Oncology	2020	View \| Download
Selpercatinib for previously untreated advanced RET-fusion positive thyroid cancer	Selpercatinib (LOXO-292; LY3527723)	Thyroid cancer	Oncology	2022	View \| Download
Selpercatinib for advanced thyroid cancer with RET alterations	Selpercatinib (LOXO-292; LY3527723)	Medullary thyroid cancer (MTC) , Thyroid cancer	Head and Neck Cancer , Oncology	2019	View \| Download
Pralsetinib for treating thyroid cancer	Pralsetinib (BLU-667; Gavreto)	Thyroid cancer	Oncology	2021	View \| Download
Pexidartinib for tenosynovial giant cell tumour	Pexidartinib (PLX3397)	Tenosynovial giant cell tumour (TGCT)	Oncology	2019	View \| Download
Pembrolizumab with lenvatinib for previously treated metastatic colorectal cancer	Lenvatinib (Kisplyx; E7080; lenvatinib mesilate) , Pembrolizumab (Keytruda; MK-3475)	Colorectal cancer	Gastroenterology , Oncology	2022	View \| Download
Pembrolizumab for treatment of solid tumours – second line	Pembrolizumab (Keytruda; MK-3475)	Solid tumours	Haematological Cancer and Lymphomas , Oncology	2021	View \| Download
Pembrolizumab for Stage IV Colorectal Carcinoma – first line	Pembrolizumab (Keytruda; MK-3475)	Colorectal cancer	Gastrointestinal Cancer , Oncology	2018	View \| Download
Nivolumab in combination with ipilimumab for cisplatin-ineligible patients with untreated, unresectable or metastatic urothelial cancer– first line	Ipilimumab (Yervoy; BMS 734016; MDX 101) , Nivolumab (Opdivo; BMS-936558; ONO-4538)	Bladder cancer	Oncology , Urological Cancer	2021	View \| Download